Blinding is compromised for transcranial direct current stimulation at 1 mA for 20 min in young healthy adults
2019 | journal article. A publication with affiliation to the University of Göttingen.
Jump to: Cite & Linked | Documents & Media | Details | Version history
Cite this publication
Blinding is compromised for transcranial direct current stimulation at 1 mA for 20 min in young healthy adults
Turi, Z. ; Csifcsák, G.; Boayue, N. M.; Aslaksen, P.; Antal, A. ; Paulus, W. & Groot, J. et al. (2019)
European Journal of Neuroscience, 50(8) pp. 3261-3268. DOI: https://doi.org/10.1111/ejn.14403
Documents & Media
Details
- Authors
- Turi, Zsolt ; Csifcsák, Gábor; Boayue, Nya Mehnwolo; Aslaksen, Per; Antal, Andrea ; Paulus, Walter ; Groot, Josephine; Hawkins, Guy E.; Forstmann, Birte; Opitz, Alexander; Thielscher, Axel; Mittner, Matthias
- Abstract
- Abstract Transcranial direct current stimulation ( tDCS ) is a non‐invasive brain stimulation method that is frequently used to study cortical excitability changes and their impact on cognitive functions in humans. While most stimulators are capable of operating in double‐blind mode, the amount of discomfort experienced during tDCS may break blinding. Therefore, specifically designed sham stimulation protocols are being used. The “fade‐in, short‐stimulation, fade‐out” ( FSF ) protocol has been used in hundreds of studies and is commonly believed to be indistinguishable from real stimulation applied at 1 mA for 20 min. We analysed subjective reports of 192 volunteers, who either received real tDCS ( n = 96) or FSF tDCS ( n = 96). Participants reported more discomfort for real tDCS and correctly guessed the condition above chance‐level. These findings indicate that FSF does not ensure complete blinding and that better active sham protocols are needed.
- Issue Date
- 2019
- Journal
- European Journal of Neuroscience
- ISSN
- 0953-816X
- eISSN
- 1460-9568
- ISSN
- 0953-816X
- eISSN
- 1460-9568
- Language
- English
- Sponsor
- Lundbeckfonden https://doi.org/10.13039/501100003554
Novo Nordisk Fonden https://doi.org/10.13039/501100009708